Exercise

Researchers are investigating how balance and walking abilities relate to detailed movement measurements in people with Multiple Sclerosis MS. This observational study focuses on understanding the connection between clinical tests of function and objective biomechanical data. The goal is to identify which movement characteristics best reflect balance, gait, and physical performance challenges faced by individuals with MS. Participants will attend a single laboratory session where they undergo biomechanical analysis using the Vicon motion capture system. They will complete functional assessments of balance, gait, and physical performance, as well as questionnaires about fear of falling and fatigue. Spasticity in the lower limbs will also be assessed during this visit. During the session, participants will perform tests such as the mini-BESTest for balance, Functional Gait Assessment, Short Physical Performance Battery, and a 2-minute walk test. Questionnaires like the Fall Efficacy Scale and Fatigue Severity Scale will be completed. Researchers will analyze these collected data to explore how biomechanical and functional measures relate, aiming to improve assessment tools for MS rehabilitation.

Researchers are evaluating whether the video-based exercise program Bliib fit - mach mit can improve physical fitness in older adults living in residential care facilities. The study aims to see if this program enhances physical fitness, quality of life, perceived fall risk, self-efficacy, and daily physical activity levels. This trial compares the video-based program to a caregiver-led activation program as an optimized standard care approach. Participants will take part in either the video-based exercise program or the caregiver-led activation program for 12 weeks. Each participant will engage in sessions four times a week, with each session lasting about 20 minutes. The video-based program focuses on mobilization, muscle strengthening, coordination, balance, and relaxation, supervised by a care professional. The caregiver-led activation program is instructed and carried out by care professionals individually or in groups. During the study, researchers will assess participants at baseline, after 12 weeks of intervention, and again 12 weeks after the intervention ends. They will measure physical fitness through tests like the Short Physical Performance Battery, grip strength, and a 2-minute walking test. Secondary measures include health-related quality of life, falls efficacy, self-efficacy, and physical activity tracked with accelerometers. This comprehensive monitoring aims to understand how the programs affect participants over time.

Researchers are working to create risk prediction models that help identify patients with a high risk of developing serious cardiovascular problems. The study focuses on individuals with structural, rhythm-related, or inflammatory cardiovascular diseases and aims to improve early detection of those at risk. This observational study is sponsored by the Medical University Innsbruck and includes adults 18 years and older. Participants in this study have their clinical data and risk factors recorded to better understand their cardiovascular condition. There are no specific treatments or interventions given as part of the study since it is observational. The study will follow patients for up to four years to observe outcomes related to cardiovascular events and hospitalizations. During the study, researchers will monitor events such as cardiovascular mortality, stroke, heart attacks, hospital stays due to heart failure, and other severe heart-related conditions. Participants will be assessed regularly through clinical data collection without additional procedures or treatments. The study aims to gather detailed information over time to improve risk assessment and patient care for cardiovascular diseases.

Researchers are evaluating how forming a physical activity PA identity within families can promote long-term physical activity among children aged 6 to 12 years. The study compares an identity formation approach, which includes education and planning plus additional coaching, to a standard education and planning condition. The main goal is to see if children in the identity formation group increase their moderate- to vigorous-intensity physical activity MVPA more over six months. Participants are divided into two groups. One group receives sessions, informational booklets, and worksheets based on Canadas PA guidelines, focusing on how parents can support their childs physical activity through encouragement, logistical help, and doing activities together. This group also receives materials on healthy family eating. The other group receives the same materials plus two extra coaching sessions that include family PA identity activities, such as assigning fun PA roles to family members and creating family PA items like t-shirts and photos, to strengthen social identity related to physical activity. During the six-month study, researchers will monitor childrens MVPA at baseline, 6 weeks, 3 months, and 6 months. Additional assessments include parent-child activity tracking through accelerometers and self-reports, body measurements, cardiovascular and musculoskeletal fitness tests, and social identity questionnaires. The study aims to understand how family support and identity impact childrens physical activity and health outcomes, with the University of Victoria leading the research.

Researchers are evaluating the effects of the traditional Vietnamese Xuong tan lac than exercise on joint range of motion and muscle endurance in healthy adults. This study aims to determine if practicing this exercise improves movement and muscle endurance around multiple joints including the cervical spine, lumbar spine, shoulders, elbows, wrists, knees, and ankles. The study focuses on healthy volunteers and explores how this traditional exercise may support musculoskeletal function. Participants will be trained to correctly perform the Xuong tan lac than exercise, which involves a series of breathing and controlled lateral trunk movements while standing in a semi-squat position. They will practice the exercise once daily, five days a week, for 12 weeks, following a standardized protocol. Assessments will be conducted at the start and after 2, 4, 8, and 12 weeks to track changes. Throughout the study, participants will undergo measurements of joint range of motion using the Noraxon MyoMotion system with inertial measurement sensors, as well as tests of muscle endurance. Researchers will assess nerve conduction parameters at the beginning and end of the study. These evaluations aim to capture improvements in joint mobility and muscle function over the 12-week exercise program. The study involves regular monitoring and adherence to the exercise schedule under research supervision.

Researchers are studying a medicine called MK-8527 to understand how it behaves in the bodies of healthy adults aged 18 to 55. The study aims to learn how MK-8527 interacts when taken with food or combined with other medicines like probenecid and itraconazole. The goal is also to assess the safety of MK-8527 and whether participants can tolerate it without needing to stop due to health issues. Participants will receive single doses of MK-8527 under different conditions with food and without food, alone and combined with probenecid, and alone and combined with itraconazole. This crossover study allows each participant to experience all these dosing scenarios to compare how the medicine behaves in each case. During the study, participants will be monitored through blood and urine tests at specified times up to 336 hours after dosing to measure MK-8527 levels and its clearance. Researchers will also track any side effects or reasons for stopping treatment over approximately 43 days. The study is conducted by Merck Sharp & Dohme LLC and is expected to complete in October 2026.

The GENESIS clinical study aims to map HLA genetic variation in the Greek population and evaluate possible correlations with selected underlying diseases. It is a multicenter, prospective, non-interventional clinical study targeting 12,000 subjects over an anticipated duration of 36 months, with the goal of creating a pilot HLA map for medical research and possible clinical applications. Each subject will complete one visit at a participating site and provide demographic information, including date of birth, gender, race, ancestry, height, and weight, as well as information about smoking or vaping, alcohol consumption, arterial blood pressure, diagnosed diseases, and current treatments. Recent clinical laboratory results from up to 12 months before sample collection may also be collected when available, including blood count, metabolic, liver enzyme, and biochemical parameters. Two buccal swabs will be collected from each subject for DNA extraction and HLA genotyping analysis. Selected DNA samples will also undergo low-pass whole genome sequencing to further investigate associations between the HLA region and autoimmune diseases. After the analysis is completed, an individualized ancestry report will be securely available to study subjects if they elect to access it.

Researchers are evaluating two medicines, enlicitide and rosuvastatin, in healthy adults aged 18 to 55 years. The study aims to compare the amounts of these medicines in the body over time when given separately and when combined into a single tablet. This research is a Phase 1 trial focused on basic science to understand how these drugs behave when taken together or alone. Participants will receive either a single dose of enlicitide with rosuvastatin tablets taken together or a single dose of a combined tablet called MK-0616A or its formulation B. The study includes two parts where these treatments are given in a randomized crossover design, meaning participants receive different treatments in sequence to compare drug absorption. During the study, participants will be monitored for drug levels in their blood at specific times up to 168 hours after dosing. Researchers will measure how much of each drug is present over time and the highest concentration reached. Safety will also be evaluated by tracking any side effects or adverse events during the approximately nine weeks of observation. Participants will have scheduled visits for dosing and blood sampling throughout the study period.

Researchers are studying a new oral medicine called MK-4082, designed for weight loss in people with higher body weight. This trial focuses on healthy adults to understand how MK-4082 behaves in the body over time. The study also compares MK-4082 levels when taken alone and when combined with another medicine called diltiazem, while checking safety and tolerance. Participants go through two parts in this study. In Part 1, they receive a single oral dose of MK-4082 alone, then a single oral dose of MK-4082 combined with multiple doses of diltiazem. In Part 2, participants receive either a single dose of MK-4082 or a placebo. Ondansetron is provided as a rescue medication to help prevent nausea or vomiting. During the study, participants are monitored for drug levels in their blood at specific times up to about one week after dosing. Researchers also track any adverse events, including whether participants stop treatment due to side effects. The study measures include maximum drug concentration and how long the drug stays in the body. Overall participation lasts several weeks, with assessments during and after dosing to ensure safety and collect data.

Researchers are studying the effects of AP-Brain collagen peptide on attention, focus, stress, and memory in adults aged 35 to 70 who are stressed but otherwise healthy. The study aims to find out how different doses of AP-Brain affect brain function and to identify any side effects. The trial is a randomized, open-label, parallel design sponsored by Rousselot BVBA. Participants will take either a low dose one 1g tablet or a higher dose three 1g tablets of bovine-based AP-Brain collagen peptide once daily for 56 days. The study includes two groups receiving these different doses to compare their effects on cognitive abilities and stress levels. During the study, participants will visit the study center regularly for checkups. They will complete tests that measure attention, focus, and memory and answer surveys about stress. Blood samples will be collected, vital signs checked, and brain responses monitored to understand the impact of AP-Brain. The main outcome focuses on changes in attention and focus after 56 days of treatment.